{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:02:51Z","timestamp":1776434571779,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,8,29]],"date-time":"2007-08-29T00:00:00Z","timestamp":1188345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1007\/s11883-007-0050-3","type":"journal-article","created":{"date-parts":[[2007,8,28]],"date-time":"2007-08-28T11:51:53Z","timestamp":1188301913000},"page":"389-396","source":"Crossref","is-referenced-by-count":67,"title":["Statin myopathy: Incidence, risk factors, and pathophysiology"],"prefix":"10.1007","volume":"9","author":[{"given":"Kimberly A.","family":"Sewright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla M.","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,29]]},"reference":[{"key":"50_CR1","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"P.D. Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681\u20131690.","journal-title":"JAMA"},{"issue":"8A","key":"50_CR2","doi-asserted-by":"crossref","first-page":"44C","DOI":"10.1016\/j.amjcard.2005.12.009","volume":"97","author":"T.A. Jacobson","year":"2006","unstructured":"Jacobson TA: Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97(8A):44C\u201351C.","journal-title":"Am J Cardiol"},{"key":"50_CR3","unstructured":"Merck & Co: I: MECACOR (LOVASTATIN). In: Prescription Information. 2005."},{"key":"50_CR4","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"A. Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788\u20132797.","journal-title":"Circulation"},{"key":"50_CR5","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","volume":"166","author":"P. Thavendiranathan","year":"2006","unstructured":"Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166:2307\u20132313.","journal-title":"Arch Intern Med"},{"key":"50_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.healthpol.2004.04.001","volume":"69","author":"M. Maggini","year":"2004","unstructured":"Maggini M, Raschetti R, Traversa G, et al.: The cerivastatin withdrawal crisis: a \u201cpost-mortem\u201d analysis. Health Policy (Amsterdam) 2004, 69:151\u2013157.","journal-title":"Health Policy (Amsterdam)"},{"key":"50_CR7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","volume":"40","author":"R.C. Pasternak","year":"2002","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40:567\u2013572.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10557-005-5202-5","volume":"19","author":"M.B. Yilmaz","year":"2005","unstructured":"Yilmaz MB, Pinar M, Naharci I, et al.: Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther 2005, 19:437\u2013440.","journal-title":"Cardiovasc Drugs Ther"},{"key":"50_CR9","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","volume":"165","author":"K.E. Hansen","year":"2005","unstructured":"Hansen KE, Hildebrand JP, Ferguson EE, Stein JH: Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005, 165:2671\u20132676.","journal-title":"Arch Intern Med"},{"key":"50_CR10","doi-asserted-by":"crossref","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"50_CR11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00005344-200208000-00001","volume":"40","author":"H. Sinzinger","year":"2002","unstructured":"Sinzinger H, Wolfram R, Peskar BA: Muscular side effects of statins. J Cardiovasc Pharmacol 2002, 40:163\u2013171.","journal-title":"J Cardiovasc Pharmacol"},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/106002809603000917","volume":"30","author":"M.A. Piercy","year":"1996","unstructured":"Piercy MA, Sramek JJ, Kurtz NM, Cutler NR: Placebo response in anxiety disorders. Ann Pharmacother 1996, 30:1013\u20131019.","journal-title":"Ann Pharmacother"},{"key":"50_CR13","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","volume":"97","author":"P.D. Thompson","year":"2006","unstructured":"Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C\u201376C.","journal-title":"Am J Cardiol"},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.amjcard.2003.06.015","volume":"92","author":"J.K. Jones","year":"2003","unstructured":"Jones JK: Spontaneous reports cannot serve as a basis for comparison of two drugs. Am J Cardiol 2003, 92:1141\u20131142.","journal-title":"Am J Cardiol"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","volume":"292","author":"J.A. Lemos de","year":"2004","unstructured":"de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307\u20131316.","journal-title":"JAMA"},{"key":"50_CR16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1511\/2007.63.60","volume":"95","author":"D.H. Kent","year":"2007","unstructured":"Kent DH: When averages hide individual differences in clinical trials. Am Scientist 2007, 95:60\u201368.","journal-title":"Am Scientist"},{"key":"50_CR17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","volume":"163","author":"C.M. Ballantyne","year":"2003","unstructured":"Ballantyne CM, Corsini A, Davidson MH, et al.: Risk for myopathy with statin therapy in high-risk patients. Arch Inter Med 2003, 163:553\u2013564.","journal-title":"Arch Inter Med"},{"key":"50_CR18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1331\/154434506778073637","volume":"46","author":"R.L. Talbert","year":"2006","unstructured":"Talbert RL: Safety issues with statin therapy. J Am Pharm Assoc 2006, 46:479\u2013488; quiz 488\u2013490.","journal-title":"J Am Pharm Assoc"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","volume":"6","author":"J. Oh","year":"2007","unstructured":"Oh J, Ban M, Miskie B, et al.: Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.","journal-title":"Lipids Health Dis"},{"key":"50_CR20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00129784-200404040-00005","volume":"4","author":"A. Vermes","year":"2004","unstructured":"Vermes A, Vermes I: Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004, 4:247\u2013255.","journal-title":"Am J Cardiovasc Drugs"},{"key":"50_CR21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20291","volume":"31","author":"S.K. Baker","year":"2005","unstructured":"Baker SK: Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005, 31:572\u2013580.","journal-title":"Muscle Nerve"},{"key":"50_CR22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11883-005-0007-3","volume":"7","author":"A.H. Maitland-van der Zee","year":"2005","unstructured":"Maitland-van der Zee AH, Boerwinkle E: Pharmacogenetics of response to statins: where do we stand? Curr Atheroscler Rep 2005, 7:204\u2013208.","journal-title":"Curr Atheroscler Rep"},{"key":"50_CR23","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1161\/CIRCULATIONAHA.105.548198","volume":"112","author":"C.I. Ardern","year":"2005","unstructured":"Ardern CI, Katzmarzyk PT, Janssen I, Church TS, Blair SN: Revised Adult Treatment Panel III Guidelines and Cardiovascular Disease Mortality in Men Attending a Preventive Medical Clinic. Circulation 2005, 112:1478\u20131485.","journal-title":"Circulation"},{"key":"50_CR24","unstructured":"US Securities and Exchange Commission: Oldest Baby Boomers Turn 60!. Available at http:\/\/sec.gov\/news\/press\/extra\/seniors\/agingboomers.htm . Accessed April 17, 2007."},{"key":"50_CR25","unstructured":"US Centers for Disease Control: National Diabetes Fact Sheet 2005. Available at http:\/\/www.cdc.gov\/diabetes\/pubs\/estimates05 . Accessed April 17, 2007."},{"key":"50_CR26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","volume":"57","author":"H. Sinzinger","year":"2004","unstructured":"Sinzinger H, O\u2019Grady J: Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004, 57:525\u2013528.","journal-title":"Br J Clin Pharmacol"},{"key":"50_CR27","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","volume":"46","author":"P.D. Thompson","year":"1997","unstructured":"Thompson PD, Zmuda JM, Domalik LJ, et al.: Lovastatin increases exercise-induced skeletal muscle injury. Metab Clin Exp 1997, 46:1206\u20131210.","journal-title":"Metab Clin Exp"},{"key":"50_CR28","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","volume":"35","author":"M.A. Omar","year":"2001","unstructured":"Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001, 35:1096\u20131107.","journal-title":"Ann Pharmacother"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"S.M. Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227\u2013239.","journal-title":"Circulation"},{"key":"50_CR30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E. Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403\u2013414.","journal-title":"Cardiovasc Drugs Ther"},{"key":"50_CR31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2337\/diaclin.21.4.168","volume":"21","author":"J. Buse","year":"2005","unstructured":"Buse J: Statin treatment in diabetes mellitus. Clin Diabetes 2005, 21:168\u2013172.","journal-title":"Clin Diabetes"},{"key":"50_CR32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.7326\/0003-4819-140-8-200404200-00012","volume":"140","author":"V. Snow","year":"2004","unstructured":"Snow V, Aronson MD, Hornbake ER, et al.: Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004, 140:644\u2013649.","journal-title":"Ann Intern Med"},{"key":"50_CR33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-140-8-200404200-00013","volume":"140","author":"S. Vijan","year":"2004","unstructured":"Vijan S, Hayward RA: Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Inter Med 2004, 140:650\u2013658.","journal-title":"Ann Inter Med"},{"key":"50_CR34","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","volume":"292","author":"D.J. Graham","year":"2004","unstructured":"Graham DJ, Staffa JA, Shatin D, et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585\u20132590.","journal-title":"JAMA"},{"key":"50_CR35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00002018-200629050-00005","volume":"29","author":"T.A. Jacobson","year":"2006","unstructured":"Jacobson TA: Overcoming \u2018ageism\u2019 bias in the treatment of hypercholesterolaemia: a review of safety issues with statins in the elderly. Drug Saf 2006, 29:421\u2013448.","journal-title":"Drug Saf"},{"key":"50_CR36","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/qjmed\/hcg150","volume":"96","author":"U. Ravnskov","year":"2003","unstructured":"Ravnskov U: High cholesterol may protect against infections and atherosclerosis. QJM 2003, 96:927\u2013934.","journal-title":"QJM"},{"key":"50_CR37","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2105\/AJPH.92.8.1244","volume":"92","author":"J.M. Guralnik","year":"2002","unstructured":"Guralnik JM, Alecxih L, Branch LG, Wiener JM: Medical and long-term care costs when older persons become more dependent. Am J Pub Health 2002, 92:1244\u20131245.","journal-title":"Am J Pub Health"},{"key":"50_CR38","first-page":"7","volume":"48","author":"M.M. Desai","year":"1999","unstructured":"Desai MM, Zhang P, Hennessy CH: Surveillance for morbidity and mortality among older adults\u2014United States, 1995\u20131996. MMWR CDC Surveill Summ 1999, 48:7\u201325.","journal-title":"MMWR CDC Surveill Summ"},{"key":"50_CR39","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/jama.291.15.1864","volume":"291","author":"D.T. Ko","year":"2004","unstructured":"Ko DT, Mamdani M, Alter DA: Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004, 291:1864\u20131870.","journal-title":"JAMA"},{"key":"50_CR40","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","volume":"115","author":"P. Deedwania","year":"2007","unstructured":"Deedwania P, Stone PH, Bairey Merz CN, et al.: Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007, 115:700\u2013707.","journal-title":"Circulation"},{"key":"50_CR41","first-page":"512","volume":"24","author":"P.M. Clarkson","year":"1992","unstructured":"Clarkson PM, Nosaka K, Braun B: Muscle function after exercise-induced muscle damage and rapid adaptation. Med Sci Sports Exerc 1992, 24:512\u2013520.","journal-title":"Med Sci Sports Exerc"},{"key":"50_CR42","first-page":"258","volume":"24","author":"S.K. Baker","year":"2001","unstructured":"Baker SK, Tarnopolsky MA: Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001, 24:258\u2013272.","journal-title":"Clin Invest Med"},{"key":"50_CR43","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.ATV.0000190608.28704.71","volume":"25","author":"M.L. Urso","year":"2005","unstructured":"Urso ML, Clarkson PM, Hittel D, et al.: Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005, 25:2560\u20132566.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"50_CR44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","volume":"78","author":"H. Paiva","year":"2005","unstructured":"Paiva H, Thelen KM, Van Coster R, et al.: High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005, 78:60\u201368.","journal-title":"Clin Pharmacol Ther"},{"key":"50_CR45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","volume":"137","author":"P.S. Phillips","year":"2002","unstructured":"Phillips PS, Haas RH, Bannykh S, et al.: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581\u2013585.","journal-title":"Ann Intern Med"},{"key":"50_CR46","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pone.0000097","volume":"1","author":"R. Laaksonen","year":"2006","unstructured":"Laaksonen R, Katajamaa M, Paiva H, et al.: A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006, 1:e97.","journal-title":"PLoS ONE"},{"key":"50_CR47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/glycob\/7.5.625","volume":"7","author":"A. Dricu","year":"1997","unstructured":"Dricu A, Wang M, Hjertman M, et al.: Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology 1997, 7:625\u2013633.","journal-title":"Glycobiology"},{"key":"50_CR48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","volume":"110","author":"J.K. Liao","year":"2002","unstructured":"Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002, 110:285\u2013288.","journal-title":"J Clin Invest"},{"key":"50_CR49","doi-asserted-by":"crossref","first-page":"C1208","DOI":"10.1152\/ajpcell.00226.2006","volume":"291","author":"A.J. Dirks","year":"2006","unstructured":"Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol 2006, 291:C1208\u20131212.","journal-title":"Am J Physiol"},{"key":"50_CR50","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1210\/en.2003-0098","volume":"144","author":"W.B. Zhong","year":"2003","unstructured":"Zhong WB, Wang CY, Chang TC, Lee WS: Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003, 144:3852\u20133859.","journal-title":"Endocrinology"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-007-0050-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-007-0050-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-007-0050-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:35:32Z","timestamp":1559432132000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-007-0050-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,29]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s11883-007-0050-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,29]]}}}